About In Silico World: a community of practiceWe believe that one effective way to accelerate adoption of in silico technologies is to establish a pre-competitive safe space where professionals working in academia, industry, regulators agencies, research hospitals, software houses, and contract research organisations can exchange information and establish best practices.In Silico WorldINSLCW_7b6ac112-24dc-11ee-ad72-7e211e83ea00In Silico World Community of PracticeOur community is open and free to anyone with professional interest in In Silico Medicine, as of January 2022 it sees the participation of 442 experts, including individuals from:Biomedical CompaniesLarge biomedical companies such as Medtronic, Smith & Nephew, Pfizer, Johnson and Johnson, Innovative Medicine Initiative, CSL Behring, Ambu, RS-Scan, Corwave EN, Zimmer Biomet, Novartis, Bayer, ATOS, Biogen, Agfa, Icon PLC, Amgen, ERT, Exponent, etc.Biomedical SMEsBiomedical SMEs such as Nova Discovery, Lynkeus, Obsidian Biomedical, Quibim, Mediolanum Cardio Research, Voisin Consulting, CRM-Microport, Mimesis srl, H.M. Pharmacon, MCHCE, etc.Independent Software VendorsIndependent Software Vendors such as Ansys, In Silico Trials Technologies, 3DS, KIT, ASD Advanced Simulation & Design GmbH, Kuano-AI, Aparito, Chemotargets, Digital Orthopaedics, ExactCure, Materialise, Bio-CFD, Matical, FEOPS, 4RealSim, Exploristics, Synopsis, Virtonomy, Cad-Ferm Medical, etc.RegulatorsRegulators and standardisation bodies such as FDA, DIN, BSCI China, NICE, Critical Path Institute, ACQUAS, etcStandardisation BodiesClinical Research InstitutionsClinical research institutions such as Istituto Ortopedico Rizzoli, Sloan Kettering Cancer Center, Royal College of Surgeons Ireland, Gratz University Hospital, Charite Berlin, Centre Nacional Investigaciones Oncologicas, Aspirus Health, Univeritatsklinikum des Saarlandes, European Society for Pediatric Oncology, etcAcademiaIndustryRegulatory AgenciesResearch HospitalsSoftware HousesContract Research OrganisationsIn Silico World Community AdministratorsAs our community keeps growing and recently reached 400 members, we felt the need to establish a small governance that reflects and represents its members. ^^ This is why every channel in the community now has an administrator, who is invited to the private channel @Governance, where all admins will discuss and take decisions for the life of the community.Marco VicecontiAlma Mater Studiorum – Università di Bologna, as Founder of the community and Admin of #GoodSimulationPractices and #GoalsRoberta De MicheleVPH Institute, as Community Manager and Admin of #General and #OffTopicGoran StanicVPH Institute, as Community Manager and Admin of #General and #OffTopicAlfons HoekstraUniversity of Amsterdam, as Admin of #ist_solutionsAngel AlberichCEO of QUIBIM, as Admin of #CancerCristina CurreliAlma Mater Studiorum – Università di Bologna, as Admin of #insilicomedicine_uniboDavid WiflingLeibniz Supercomputing Centre, as Admin of #CoDesignEmily LumleyUniversity College London, as Admin of #CompBioMed-AHMGiorgio DavicoAlma Mater Studiorum – Università di Bologna, as Admin of #dhealth4trialsFrancesco PappalardoUniversity of Catania, as Admin of #IST_Research_ProjectsGiulia RussoUniversity of Catania, as Admin of #Stritvuad_UISS-TBMarco VerdicchioSURF Dutch Supercomputing Centre, as Admin of #CompBioMed-WP4Accelerated adoption of In Silico Technologies_7b6ac216-24dc-11ee-ad72-7e211e83ea00To establish industrial practices that make easier and reliable the development and use of In Silico Trials solutions_7b6ac36a-24dc-11ee-ad72-7e211e83ea00MedicineBest PracticesEaseReliabilityIn Silico TrialsSupport the practice of In Silico Trials_7b6ac45a-24dc-11ee-ad72-7e211e83ea00The practice of In Silico Trials is still far from being established. Most of the research so far has been conducted in academic laboratories and thus far from the needs of industrial users. This is why our community works to consolidate a set of industrial practices that make easier and reliable the development and use of In Silico Trials solutions. ^^ In Silico World is currently supporting several initiatives in this area:Good Simulation PracticeCapture aspects of activities considered to be the best possible simulation practices_7b6ac4fa-24dc-11ee-ad72-7e211e83ea001Avicenna AllianceVPH InstituteGood Practices are consensus documents produced by a group of experts – organised in a formal or informal Community of Practice – in order to capture salient aspects of performing a specific activity in the way that the group considers the best possible. ^^ Following the experience accumulated around important documents such as the Good Clinical Practice, the Good Manufacturing Practice, or the Good Laboratory Practice, a group of experts coordinated by the Avicenna Alliance and the VPH Institute is developing the first proposal for Good Simulation Practice (GSP).ScalabilityAddress the needs for scalability and efficiency of the solutions being developed_7b6ac590-24dc-11ee-ad72-7e211e83ea002CompBioMedIn the frame of the European Centre of Excellence in Computational medicine, In Silico World is monitoring all use cases where computational scalability and/or computational efficiency are a bottleneck for the wider adoption of In Silico Trials. ^^ CompBioMed offers free support to improve the scalability of your computational biomedicine solutions with high performance computers.Centre of Excellence in Computational BiomedicineThanks to the funding of the European Commission, the CompBioMed Centre of Excellence in Computational Biomedicine now offers free support to organisations in their initial steps towards improving the scalability of existing computational biomedicine applications and deploying them on high performance computing resources. The consortium will use an advanced simulation environment to address the needs for scalability and efficiency of the solutions being developed ^^ Are you struggling because your code cannot run in an acceptable time? Perhaps you are trying to simulate over 1000 virtual patients? Or do you need to perform some large-scale sensitivity analysis to get your solution certified by a regulatory authority? ^^ Whatever is the reason, we can help. ^^ A team of experts will answer your questions through the #scalability public channel on the In Silico World Community of Practice hosted on Slack.Digital HealthHost a virtual space for discussion and exchange of good practices about the use of digital health technologies in regulatory clinical trials for the safety or efficacy evaluation of new drugs or new medical devices_7b6ac63a-24dc-11ee-ad72-7e211e83ea003Mobilise-DEuropean Federation of Pharmaceutical Industries and Associations (EFPIA)Endorsed and supported by Mobilise-D, a project funded by the European Commission and various members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) through the Innovative Medicine Initiative (IMI), the #dHealth4Trials channel is a virtual space for discussion and exchange of good practices about the use of digital health technologies in regulatory clinical trials for the safety or efficacy evaluation of new drugs or new medical devices.2023-07-17https://insilico.world/community/OwenAmburOwen.Ambur@verizon.net